Market Overview

End To Male Pattern Baldness Could Be In Sight Says Leading UK Online Pharmacy Maxpharm.co.uk

Share:

New use found for established treatment for blindness, Lumigan eye-drops could be the next Propecia as a treatment for male pattern baldness.

St Helier Jersey (PRWEB UK) 3 November 2012

The active ingredient in the most commonly prescribed treatment for glaucoma, could soon be used for the treatment of the most common form of hair loss in men, male pattern baldness.

Excited scientists have found a unique side effect from the use of the drops, they can stimulate hair growth. At the moment only eye-lash growth has been noted, but research suggests that the active ingredient, called Bimatoprost, could be used to promote hair growth on the scalp.

Lead scientist professor Valerie Randall, from the university of Bradford, who is also a leading expert on hairloss said, 'our findings show that Bimatoprost does stimulate growth in human scalp hair follicles and therefore could offer a new approach for treating hair loss disorders.'

Tom O' Brien, owner of the UK online pharmacy maxpharm.co.uk says that although this is an ongoing study, it is really exciting news for anyone suffering from male pattern baldness and maxpharm.co.uk will be following the study with great interest.

The only proven oral treatment available today for male pattern baldness is propecia, a 1mg tablet which is taken once daily and the topical solution minoxidil which is applied to the scalp once daily.

maxpharm.co.uk is owned and operated by
Direct Response Marketing Jersey Limited
Suite 15
Burlington House
St Saviours Road
St Helier
Jersey

TEL: 01534 510271
JE24LA

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/11/prweb10084492.htm

View Comments and Join the Discussion!
 
Loading...